resTORbio is a clinical-stage biopharmaceutical company developing medicines that target the biology of aging to prevent or treat age-related diseases with the potential to extend healthy lifespan. Co.'s main program selectively inhibits the target of rapamycin complex 1 (TORC1), a conserved pathway that contributes to the age-related decline in function of multiple organ systems. Co.'s product candidate, RTB101, is an oral and selective inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Co. has licensed the rights to its TORC1 program, including RTB101 alone or in combination with everolimus, from Novartis International Pharmaceutical Ltd.
|
Free TORC Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.33 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |